haloacid dehalogenase like hydrolase domain containing 2Genealiases: 3110052N05Rik · HEL-S-301
Q-omics provides the consensus-scored HDHD2 profile across patient tissues and cancer cell-line models. HDHD2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HDHD2 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, HDHD2 protein abundance shows 26,843 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, KICH, and PDAC as cancer lineages where HDHD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HDHD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HDHD2 survival associations across molecular data types. HDHD2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HDHD2 RNA expression–survival associations across cancer types. High HDHD2 expression shows favorable associations in KIRC, OV, BRCA, PAAD, KIRP and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HDHD2 RNA expression.
This table summarizes HDHD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HDHD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HDHD2 shows lower tumor expression in KICH, KIRP, COAD, THCA, LUAD and KIRC. The KICH box plot shows higher HDHD2 RNA expression in normal versus tumor tissue (log2 FC = −1.417, t-test p < 0.001).
This table shows molecular features associated with HDHD2 in patient tissues and cancer cell lines. In patient samples, HDHD2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, HDHD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
